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In the current study, we extended our previous works on natural endogenous reverse transcription (NERT) and further examined its potential as
a virucide molecular target in sexual transmission of primate lentiviruses. HIV-1 and SIV virions were pretreated with select nucleoside (NRTIs)
and nonnucleoside RT inhibitors (NNRTIs), either alone or in combination with NERT-stimulating substances. The effects of these antiretrovirals
on virion inactivation were analyzed in human T cell lines and primary cell cultures. Pretreatment of HIV-1 virions with physiologic NERT-
stimulants and 3′-azido-3′-deoxythymidine 5′-triphosphate (AZT-TP) or nevirapine potently inactivated cell-free HIV-1 virions and resulted in
strong inhibition of the viral infectivity. Pretreatment of chimeric SHIV-RT virions with NERT-stimulating cocktail and select antiretrovirals also
resulted in virion inactivation and inhibition of viral infectivity in T cell lines. Our findings demonstrate the potential clinical utility of approaches
based on inhibiting NERT in sexual transmission of HIV-1, through the development of effective anti-HIV-1 microbicides, such as NRTIs and
NNRTIs.
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Reverse transcriptase (RT) represents a virally encoded
protein with three enzymatic activities, RNA- and DNA-
dependent DNA polymerase and RNase H (Baltimore, 1970;
Coffin, 1990; Temin and Mizutani, 1970). Previous studies
have shown that these activities can be measured either within
virions made permeable by low levels of detergent or
amphipathic peptides, such as melittin, to allow access of
deoxyribonucleoside triphosphates (dNTPs) (Boone and
Skalka, 1981a, 1981b; Garapin et al., 1970; Gilboa et al.,
1979) or by complete disruption of the virions with high
concentrations of nonionic detergents (Poiesz et al., 1980),⁎ Corresponding author. Fax: +1 215 923 1956.
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doi:10.1016/j.virol.2006.06.014representing endogenous and exogenous RT activity, respec-
tively. Endogenous RT (ERT) reactions have been a key in
the evaluation of the kinetics and molecular intermediates of
reverse transcription (Boone and Skalka, 1981a, 1981b;
Borroto-Esoda and Boone, 1991; Gilboa et al., 1979). Early
studies have demonstrated that nonionic detergents are helpful
in permeabilizing retroviral virions to allow near full-length
viral DNA synthesis (Gilboa, 1979; Yong et al., 1990).
Nevertheless, endogenous RT activity was also noted in
nonpermeabilized HIV-1 virions, by several groups, including
ours (Yong et al., 1990; Borroto-Esoda and Boone, 1991;
Debyser et al., 1992; Zhang et al., 1993; Zhang et al., 1996b,
1996c). We and others have demonstrated that in a detergent-
free system, addition of dNTPs to isolated HIV-1 virions
could stimulate RT activity, leading to higher levels of virions
carrying strong stop negative strand moieties and more
complete negative strand intermediates (Borroto-Esoda and
Boone, 1991; Zhang et al., 1996b). The intravirion reverse
Fig. 1. Inhibitory effects of select antiretroviral agents on NERT. Intravirion
HIV-1 reverse transcripts were assayed by DNA-PCR. Virions were pretreated
with nevirapine, AZT-TP and/or AZT at 4 μM, with or without NERT-
stimulating cocktail. After 4 h, the DNA was extracted and subjected to semi-
quantitative PCR and Southern blotting analysis. The figure is representative of
two independent studies.
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but also in vivo (Zhang et al., 1994, 1996a). The efficiency of
intravirion reverse transcription in HIV-1 virions is augmented
by certain physiologic substances such as polyamines (e.g.,
spermine and spermidine). It is notable that polyamines reach
very high concentrations in seminal fluids. HIV-1 virions in
seminal plasma were found to harbor dramatically higher
levels of full-length or nearly full-length reverse transcripts,
as compared with virions isolated from the peripheral blood
of HIV-1-seropositive men (Zhang et al., 1996b). HIV-1
virions, which have processed a certain amount of ERT,
would have a kinetic advantage to infect initially resting CD4
T cells and macrophages (Zhang et al., 1996b; Dornadula et
al., 1999). As intravirion reverse transcription is a biochemi-
cally active process that can take place without nonphysio-
logical virion permeabilization, it has been entitled “natural
endogenous reverse transcription (NERT)” (Zhang et al.,
1996b, 1998).
We have further demonstrated that the amphipathic domains
at the C-terminus of HIV-1 gp41 are able to make the viral
envelope naturally permeable to dNTPs, which underlines the
molecular mechanism of NERT phenomenon (Zhang et al.,
1996c). Deletion of these amphipathic domains can eliminate
the exogenous dNTP-driven intravirion reverse transcription
(Zhang et al., 1996c). It has been demonstrated that the peptides
derived from the amphipathic domains at the C-terminus of
gp41 [named as lentiviral lytic peptide (LLP)] are able to lyse
either prokaryotic or eukaryotic cells (Miller et al., 1991; Miller
et al., 1993). These peptides can also form a pore in planar
phospholipid bilayer membrane (Chernomordik et al., 1994).
We have found that the synthesized LLP, like melittin, can allow
dNTPs to pass through viral envelope which lacks the LLP
domain (Zhang et al., 1996c).
At this stage in AIDS pandemic, prevention of sexual
transmission of HIV-1 is of highest priority. Many investigators
have attempted to develop various virucides to inactivate the
cell-free virions and therefore prevent the sexual transmission of
HIV-1 (Balzarini et al., 1998; Fauci, 1993; Fichorova et al.,
2005; van Damme and Rosenberg, 1999). As the viral envelope
is naturally permeable to triphosphates of nucleosides and
polyamines in human seminal plasma can significantly enhance
the NERTactivity such that a large amount of reverse transcripts
can be found within cell-free HIV-1 virions in seminal fluids,
we propose that intravirion reverse transcription is an ideal
target for inactivating the virions in seminal fluids. We have
now extended our previous studies (Dornadula et al., 1997,
1999; Zhang et al., 1993, 1994, 1996a, 1996b, 1996c, 1998) and
herein present recent findings on inhibiting NERT by means of
select agents and its potential usage to prevent sexual
transmission of human and nonhuman primate lentiviruses.
Results
As HIV-1 virions are naturally permeable to triphosphates
of nucleosides (e.g., dNTPs), we hypothesized that tripho-
sphates of chain terminators could also pass through the viral
envelope. We first conducted experiments to test the effectof the NRTI [e.g., 3′-azido-3′-deoxythymidine 5′-tripho-
sphate (AZT-TP)] or NNRTI (e.g., nevirapine) on inhibiting
NERT. As shown in Fig. 1, pretreatment of virions (200 ng of
HIV-1 p24 equivalent) with 4 μM of the NNRTI, nevirapine,
led to decreased NERT, as compared to NERT-stimulated
controls (virions pretreated with polyamines and dNTPs at
physiological concentration in seminal fluids) (Zhang et al.,
1996b) by analysis of intravirion DNA, but somewhat less
than AZT-TP (approximately 90% versus 95% decrease in
gag copy numbers by phosphor-imager analyses). As
expected, pretreatment of virions with AZT, which was
used as a negative control in our experiments, did not affect
NERT.
We have also analyzed the effects of nevirapine and AZT-
TP on inactivating virions in initially quiescent human PBL
cultures, which were infected with antiretroviral agent
(nevirapine, AZT-TP and/or AZT at 4 μM) pretreated or
untreated virions. HIV-1NL4-3 (X4-tropic) virions were
pretreated with different concentrations of antiviral reagents,
with or without NERT-stimulating cocktail at physiological
concentrations in seminal fluids and then used to infect
initially quiescent human peripheral blood lymphocytes
(PBLs). Both nevirapine and AZT-TP demonstrated a potent
inhibitory effect (approximately a 25-fold decrease) on viral
infectious titer (Fig. 2a), indicating that these NERT inhibitors
indeed function as virucides and effectively inactivate the
virions. We have also tested various concentrations of NERT
inhibitors upon viral infectivity. As shown in Fig. 2b, both
AZT-TP and nevirapine again exerted a dramatic inhibitory
effect on viral growth in PBL cultures 12 days post-infection,
but only in the presence of the NERT-stimulating cocktail.
AZT-TP, at a concentration of 1 μM and in the presence of
polyamines/dNTPs, was found to be a more potent inhibitor
of NERT, as compared to nevirapine at the same
Fig. 2. Effects of select antiretroviral agents on NERTand HIV-1 infectivity in human primary cells. (a) Infectivity of HIV-1 virions pretreated with select antiretroviral
agents. One nanogram of HIV-1NL4-3 p24 antigen was serially diluted from pretreated virion preparations and used to infect initially quiescent PBLs. Viral infectious
titer was assessed via HIV-1 p24 antigen expression (ELISA) at day 28 post-infection. The figure is representative of at least two independent studies. (b) Infectivity of
HIV-1 virions pretreated with select antiretroviral agents with or without the NERT-stimulating cocktail. Ten ng of HIV-1NL4-3 p24 antigen equivalents from virion
preparations, pretreated (or nontreated) with various concentrations of select antiretroviral agents in the presence or absence of the NERT-stimulating cocktail, were
used to infect human PBL cultures. Viral production was assessed via HIV-1 p24 antigen expression (ELISA) by day 12 post-infection. The figure is representative of
two independent studies. NL4-3: cells infected with untreated viral preparation only; Nev: nevirapine; NERT: NERT-stimulating cocktail (100 nM dNTPs, 3 mM
spermine and 0.1 mM spermidine). (c) Ten nanograms of HIV-1ADA p24 antigen equivalents from virion preparations, pretreated (or nontreated) with various
concentrations of select antiretroviral agents in the presence or absence of the NERT-stimulating cocktail, were used to infect human monocyte/macrophage cultures.
Viral production was assessed via HIV-1 p24 antigen expression (ELISA) by day 5 post-infection. The figure is representative of two independent studies. ADA: cells
infected with untreated HIV-1 only; Nev: nevirapine, NERT: NERT-stimulating cocktail (100 nM dNTPs, 3 mM spermine and 0.1 mM spermidine).
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Fig. 3. Time-course analysis of the effects of a NERT-stimulating cocktail on
HIV-1 stability and NERT-altering agents on HIV-1 infectivity at different
temperature conditions. (a) HIV-1NL4-3 virion preparations (1 ng of HIV-1 p24
antigen equivalents) were either pretreated with the NERT-stimulating cocktail,
or left untreated. Subsequently, the virion preparations were incubated in RPMI-
1640 medium at 37 °C for different time periods. Infectivity was assessed on
initially quiescent PBLs, via HIV-1 p24 antigen expression on day 10 post-
infection. The 0 h represents prompt re-isolation of virions after mixing with
media containing, or not containing the NERT-stimulating cocktail. (b) HIV-
1NL4-3 virion preparations (4 ng of HIV-1 p24 antigen equivalents) were
pretreated with 4 μM of AZT-TP in the presence or absence of the NERT-
stimulating cocktail (100 nM dNTPs, 3 mM spermine and 0.1 mM spermidine)
for 15 h at different temperature conditions (37 °C and 4 °C). After re-isolation
by ultracentrifugation, the virion preparations were used to infect initially
quiescent human PBLs. Viral production was assessed via HIV-1 p24 antigen
expression (ELISA) by day 10 post-infection.
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virtually ablated viral replication. Our findings demonstrate
that polyamines and dNTPs are essential not only for the
inhibitory effects of the NRTI, AZT-TP, but also for the
NNRTI, nevirapine. Similar results were obtained in testing
the inhibitory effects of nevirapine and AZT-TP on NERT in
macrophage cultures. HIV-1ADA virions (R5-tropic) were
pretreated with different concentrations of drugs in the
presence or absence of physiologic NERT stimulators and
used to infect macrophages. As illustrated in Fig. 2c, both
drugs at a concentration of 10 μM in the presence of a NERT
stimulatory cocktail, reduced HIV-1ADA growth by at least
50%, while NERT inhibition was less profound in the absence
of polyamines and dNTPs. This finding indicates that R-tropic
viruses are also sensitive to NERT inhibitors and is of great
significance, as R-tropic viruses play a leading role for sexual
transmission (Zhu et al., 1993).
To examine whether dNTPs and/or polyamines (NERT-
stimulating cocktail simulating physiological concentration in
seminal fluids) might actually stabilize virions in the
incubation period during induction of ERT, time-course
experiments were conducted. Changes in stability of HIV-1
virions might confound analysis of NERT-altering virion
infectivity. To explore this issue, certain HIV-1NL4-3 virion
preparations were not treated with dNTPs and/or polyamines
but incubated for different time periods (0 to 16 h) at 37 °C
in serum-negative, RPMI-1640 media (i.e., same conditions as
during stimulation of NERT). No decreases in infectivity of
virion preparations were demonstrated with up to 16 h of
incubation, which is the limit used in NERT stimulation (after
16 h the virion infectivity began to slowly deteriorate). A
modest increase in virion infectivity at 4 to 8 h of incubation
may be secondary to low levels of baseline NERT occurring
during incubation or maturation of HIV-1 virions (Fig. 3a).
These data suggest that decreasing virion stability during
NERT stimulation conditions, which could be altered by
polyamines (spermine and spermidine) and/or dNTPs at
physiological concentration in seminal fluids, does not take
place. In addition, it was theoretically possible that super-
physiological stabilization of virions might be possibly
induced by polyamines and/or dNTPs at 37 °C. As such,
time-courses (i.e., different incubation times; 0 to 16 h) of
HIV-1NL4-3 virions treated with physiological concentrations
(as above) of polyamines and dNTPs at 37 °C were also
conducted. There was no difference in infectivity in treated
and untreated virion preparations at the 0-h time point (i.e.,
prompt isolation of virions after treatment), and only minor
differences at 1 h (Fig. 3a). Only at 4 h post-incubation, the
activity of NERT-cocktail-pretreated virions was significantly
increased. These data argue against super-physiologically
increased stabilization of virions by polyamines/dNTPs, as
compared to the “normal” stability of HIV-1 virions. As well,
these data also point against at least gross binding to virion
surfaces and carry-over of RT-stimulating reagents into target
cells.
To further evaluate whether dNTPs and/or polyamines might
be “carried-over” into target cells, either intravirion or bound to
Table 1
Effects of NERT-altering agents on SIV: viral infectivity assay upon CEM-174 cells—SIVMAC251 (shown: Day 28 post-infection)
Treatment SIVMAC251 viral input—dilutions (25 ng of SIV-1 p27 antigen)
1:1 1:5 1:25 1:125 1:625 1:3125
Virions only ++++ ++++ +++ − − −
Virions+NERT cocktail ++++ ++++ ++++ − − −
Virions+nevirapine ++++ ++++ + − − −
Virions+NERT cocktail+nevirapine ++++ ++++ + − − −
Virions+AZT-TP ++++ ++++ ++ − − −
Virions+NERT cocktail+AZT-TP ++++ +++ − − − −
Virions+AZT ++++ ++++ + − − −
Virions+NERT cocktail+AZT ++++ ++++ +++ − − −
−: <125 pg/ml; +: 125 to 250 pg/ml; ++: 250 to 500 pg/ml; +++: 500 to 1000 pg/ml; ++++: >1 ng/ml p27 antigen units.
Four μM concentrations of nevirapine, AZT-TP and AZT were used.
NERT-stimulating cocktail: 100 nM of dNTPs+3 mM spermine+0.1 mM spermidine.
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accounting for increased virion infectivity, functional tempera-
ture experiments were performed. Treatment of HIV-1 virions
with dNTPs/polyamines was conducted at 4 °C and 37 °C. As
RT does not process at 4 °C, any change in infectivity on target
cells would be due to intracellular RT induction from “carry-
over” of dNTPs/polyamines. In these studies, HIV-1NL4-3
virions were treated with a NERT-stimulating cocktail and
inhibiting agents (AZT-TP at 4 μM), and maintained at 4 °C and
37 °C for 15 h of incubation. As shown in Fig. 3b, there was no
change in virion infectivity on initially quiescent human
PBMCs as target cells, when virions were treated and incubated
at 4 °C.
As the simian immunodeficiency virus (SIV) RT is not
inhibited by most NNRTIs, yet these may be critical moieties
as molecular virucides against HIV-1, we also utilized an
SHIV-RT construct (Uberla et al., 1995), in initial in vitro
studies. SHIV-RT is a key construct in use within many
macaque model systems of lentiviral transmission and
pathogenesis (Balzarini et al., 1997; Mori et al., 2000;
Rosenwirth et al., 1999; Uberla et al., 1995). By utilizing
SIV mac251 and SHIV-RT mac239env on CEM-174 target
cells to determine the viral infectious titer, we conductedTable 2
Effects of NERT-altering agents on SHIV-RT: viral infectivity assay upon CEM-174
Treatment SHIV-RT/SIV-mac239env viral
1:1 1:5
Virions only ++++ ++++
Virions+NERT cocktail ++++ ++++
Virions+nevirapine ++++ ++++
Virions+NERT cocktail+nevirapine ++++ ++++
Virions+AZT-TP ++++ ++++
Virions+NERT cocktail+AZT-TP ++++ ++++
Virions+AZT ++++ ++++
Virions+NERT cocktail+ZT ++++ ++++
−: <125 pg/ml; +: 125 to 250 pg/ml; ++: 250 to 500 pg/ml; +++: 500 to 1000 pg/m
Four μM concentrations of nevirapine, AZT-TP and AZT were used.
NERT cocktail: 100 nM of dNTPs+3 mM spermine+0.1 mM spermidine.similar studies to those performed with HIV-1 virions (Fig.
2a). SIVmac251 virions treated with 4 μM of nevirapine
showed no dramatic decrease in viral infectivity, unlike that
observed with 4 μM of AZT-TP with dNTPs/polyamines
(Table 1). This might be anticipated as NNRTIs have little
effect on the SIV RT. As expected, no inhibition was
observed on virions pretreated with AZT, and/or AZT with
NERT-stimulating cocktail, which served as negative controls.
Next, the SHIV-RT virions were evaluated. As hypothesized,
by utilizing a SHIV-RT construct (i.e., chimeric with an HIV-
1 RT gene), the virions' infectivity was now sensitive to
treatment with nevirapine (at least a five-fold dilution
decrease) (Table 2). No differences were observed on virions
pretreated with 4 μM of nevirapine, as compared to virions
treated with 4 μM of nevirapine in the presence of NERT
stimulators. Once again, no inhibition was observed with
virions pretreated with AZT, and/or AZT with the NERT-
stimulating cocktail.
Discussion
The molecular mechanisms that facilitate HIV-1 sexual
transmission have been incompletely characterized. As such,cells—SHIV-RT (shown: Day 28 post-infection)
input—dilutions (25 ng of SIV-1 p27 antigen)
1:25 1:125 1:625 1:3125
+++ + − −
+++ +++ − −
+ − − −
+ − − −
+++ + − −
+ − − −
+++ + − −
+++ ++ − −
l; ++++: >1 ng/ml p27 antigen units.
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secretions are of critical importance. One stage of the lentiviral
life-cycle, which may be altered by specific extracellular
milieus, is intravirion reverse transcription (Zhang et al.,
1993, 1996b). Determining the effects of NERT of primate
lentiviruses on viral transmission promises to assist in the
rational design of lentivirucides. In this report, we have further
extended our studies, and herein, we analyzed in vitro potential
molecular virucide agents towards primate lentiviruses by
targeting ERT. We have examined HIV-1, SIV, and SHIV-RT
with respect to NERT inhibition as well as inhibiting viral
infectivity by select antiretroviral “virucidal” agents on
human primary cells or CEM-174 cell lines. Potential
lentivirucides included the triphosphorylated derivative
NRTI, AZT-TP, as well as the NNRTI, nevirapine. We
have also examined the effects of NERT stimulators on
NERT and NERT inhibition by AZT-TP and nevirapine. It is
not surprising that AZT-TP has stronger inhibitory effect
upon viral infectivity when the NERT is initiated. As AZT-
TP functions as a chain terminator, it would have higher
chance to incorporate into the extending nascent DNA chain
during NERT process. In the presence of NERT stimulators,
the RT enzyme will start the DNA polymerization in a very
short time. The extending DNA chain, no matter how short
it is, will be the target for the chain terminator AZT-TP. It is
interesting that nevirapine also has stronger inhibitory effect
upon viral infectivity after NERT is initiated. This pheno-
menon could be due to that NERT process requires an active
form of RT enzyme, which could facilitate a tighter
interaction between nevirapine and RT enzyme. We would
like to emphasize that, the NERT stimulators, which contain
dNTPs at 100 nM or polyamines (spermine at 3 mM, and
spermidine at 0.1 mM), have naturally existed in seminal
fluids of HIV-1-seronegative men (Zhang et al., 1996b). If
these virucides identified in this report are used in clinic,
NERT cocktail used in this study is not necessary to be
simultaneously administrated, as seminal fluids have natu-
rally harbored these reagents. Conversely, since most
NNRTIs cannot be utilized against SIV NERT, as they
rather specifically inhibit HIV-1 RT, we employed a SHIV-
RT construct that was used to infect CEM-174 cells
(Balzarini et al., 1997; Uberla et al., 1995). Our findings
demonstrate that both NRTIs and NNRTIs have strong
potentials to function as virucides, in developing future
molecular approaches to inhibit NERT and its potential
role in sexual transmission. The design and development
of novel RT inhibitors and studying their effects on
intravirion reverse transcription are thus of importance for
future clinical approaches.
We have also conducted time-course experiments to
analyze whether NERT stimulants at physiological concentra-
tion in seminal fluids might actually stabilize HIV-1 virions in
the incubation period during induction of ERT, since changes
in virion stability might confound analysis of NERT-altering
virion infectivity. As shown in Fig. 3, we did not observe any
decrease in infectivity of virion preparations for up to 16 h of
incubation. A modest increase observed in virion infectivity at4 to 8 h of incubation, may be secondary to low levels of
baseline NERT occurring during incubation. Therefore, our
findings do not support decreasing virion stability during
NERT stimulation conditions, which could be altered by
polyamines and dNTPs. In addition, our findings point
against super-physiologically increased stabilization of virions
by polyamines and dNTPs, as compared to the “normal”
stability of HIV-1 virions. Furthermore, these data also
complement our “temperature-dependent” studies and strongly
suggest against gross binding to HIV-1 envelope and carry-
over of NERT stimulants into target cells. Thus, throughout
our past and present studies on intravirion reverse transcrip-
tion, we have continuously attempted to evaluate alternate
potential hypotheses, which would mitigate against NERT
stimulation or inhibition leading directly to altered virion
infectivity (Dornadula et al., 1997, 1999; Zhang et al., 1996a,
1996b, 1996c, 1998).
We have already shown that purified SIV virions also
contain virus-specific DNA, which is a result of partial
reverse transcription. Further, it was demonstrated that viral
DNA synthesis can be initiated in SIV virions in the
presence of polyamines and dNTPs at physiological
concentrations (Dornadula et al., 1997). The viral infectivity
upon initially quiescent cells was significantly increased,
when levels of intravirion reverse transcripts were modu-
lated, suggesting that NERT of SIV may play an important
role for SIV pathogenesis and transmission. This is of
importance since, in contrast to HIV-1, these phenomena
may be further directly investigated by in vivo model
systems (Miller et al., 1994, 1998). In our current in vitro
studies, we utilized a SHIV-RT construct, which represents a
key approach for use within certain macaque model
systems. Similarly to our HIV-1 studies, we analyzed the
effects NERT-altering agents in SIVmac251 and SHIV-RT
on CEM-174 target cells. Consistently, we found that AZT-
TP with NERT stimulant pretreatment of SIVmac251 virions
results in dramatic decreases of viral infectivity, while
utilization of the chimeric SHIV-RT lead to inhibition of
SIV infectivity upon pretreatment with the NNRTI,
nevirapine.
In summary, our studies demonstrate that intravirion
reverse transcription may alter molecular mechanisms under-
lying efficient transmission of human and nonhuman primate
lentiviruses. Inhibiting intravirion reverse transcription repre-
sents an important virucidal approach, as virions are made
“nonviable”, and significantly less infectious after treatment.
Our studies demonstrate the strong potential clinical utility of
approaches based on inhibiting sexual transmission of HIV-1,
on a molecular level with virion-specific agents. As such,
these may lead to the development of prophylactic
therapeutics to alter both heterosexual and homosexual
transmission of HIV-1 and possibly in altering vertical
transmission of HIV-1 from mother to infant perinatally. The
development of effective antilentiviral virucides may be one
of the most important potential development tasks, prior to a
vaccine, for stemming the HIV-1 pandemic in the developing
world.
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Reagents
AZT was obtained from Sigma, AZT-TP from Moravek
Biochemicals (CA), and nevirapine was obtained from the NIH
AIDS Research and Reference Reagent program.
Human peripheral blood samples
All blood samples were obtained from healthy HIV-1-
seronegative normal donors from the Hospital Blood Bank at
Thomas Jefferson University, via approved protocols.
Viral stocks
X4-tropic HIV-1 strain NL4-3, and the R5-tropic strain ADA
were produced by transfection of 293T cells with the respective
proviral DNA, as described previously (Argyris et al., 2003;
Zhang et al., 2000) The SIVmac251 virus was kindly provided by
Dr. C. J. Miller at the Primate Research Center, University of
California at Davis (Miller et al., 1994, 1998) and the SHIV-RT
(genomic backbone SIVmac239 with the RT gene of HIV-1) was
obtained from Dr. Joseph Sodroski (Dana-Farber Cancer
Institute) (Balzarini et al., 1997; Letvin et al., 1995; Uberla et
al., 1995).
Quantitation of intravirion HIV-1 DNA by PCR
Intravirion HIV-1 reverse transcripts were quantitated by
DNA-PCR, as described previously (Zhang et al., 1996a,
1996b, 1996c; Dornadula et al., 1997, 1999). Briefly, HIV-
1NL4-3 virions (200 ng of HIV-1 p24 antigen equivalents) were
pretreated with select antiretroviral agents at concentrations of
4 μM, with or without a NERT-stimulating cocktail consisting
of 100 nM dNTPs and polyamines (3 mM spermine and 0.1 mM
spermidine). After incubating at 37 °C for 4 h, DNA was
extracted with a “quick lysis” methodology and quantitative
PCR was performed.
Viral infectivity assays
Viral infectivity assays were performed to determine the
influence of physiological substances upon intravirion HIV-1
and SIV reverse transcription and lentiviral replication, as
well as the effects of select NRTIs and NNRTIs on NERT
(Zhang et al., 1996a, 1996b, 1996c). Infectivity was
measured in CEM-174 cell cultures, peripheral blood
mononuclear cells (PBMCs), or monocyte/macrophages
respectively.
CEM-174 cell cultures
SIVmac251 and SHIV-RT (genomic backbone SIVmac239)
were pretreated with select antiretroviral agents at concentra-
tions of 4 μM, with or without NERT-stimulating cocktail as
described previously (Dornadula et al., 1997) and further
purified via ultracentrifugation. The infectivity of each viralpreparation was analyzed utilizing CEM-174 cells, via
increasing dilutions of a set viral input (25 ng of p27
antigen). After 28 days, p27 antigen expression was
quantitated via ELISA, as described previously (Dornadula
et al., 1997).
PBLs
HIV-1NL4-3 virions in the fresh supernatants of virus-
producing cells (CEM cells) were pretreated with various
reagents and purified with ultracentrifugation to remove the
reagents, as described previously (Zhang et al., 1996a, 1996b,
1996c). The virions (10 ng of HIV-1 p24 antigen equivalents)
were then resuspended in RPMI-1640 medium and allowed to
infect 4×106 quiescent PBL (and/or PBLs) from an HIV-1-
seronegative person at 37 °C for 4 h. The unbound viruses
were washed off, via three vigorous washes with PBS. The
infected cells (2×06) were then cultured, in duplicate, in 2 ml
of RPMI-1640 medium plus 10% fetal calf serum (FCS).
After overnight incubation, the supernatants (0.5 ml) were
collected for HIV-1 p24 antigen detection on day 0. Forty-
eight hours post-infection, PHA (5 μg/ml; Sigma) and natural
human IL-2 (50 U/ml; BRL-GIBCO) were added to the
cultures. On the fifth day post-infection, PHA and IL-2 were
washed off by pelleting the infected cells via centrifugation.
The cells were then cultured in 2 ml of RPMI-1640 medium
plus 20% FCS with IL-2 (10 U/ml). Samples (0.5 ml) of the
supernatants were collected at specified time points. The HIV-
1 p24 antigen levels were quantitated by ELISA (kits from
Dupont).
Monocyte/Macrophages
Isolation of monocytes/macrophages was performed by a
previously described protocol (Collman et al., 1989; Zhang et
al., 1996b). Briefly, Ficoll discontinuous gradient-purified
peripheral blood mononuclear cells were placed onto 2%
gelatin-coated flasks to allow attachment of monocyte/macro-
phages. Nonadherent cells were vigorously washed off. The
monocyte/macrophages (4×105 cells per well) were then
cultured in a mixture of 10% FCS, 10% horse serum, 0.1 mM
nonessential amino acids (NEAA) (GIBCO), 10 U of
granulocyte–macrophage colony-stimulating factor, GM-CSF,
per ml (Sigma), and 10 U of macrophage colony-stimulating
factor, M-CSF per ml (Sigma), for 7 days. HIV-1ADA virions
were preincubated with various reagents and purified as above.
The virions (10 ng of HIV-1 p24 antigen equivalents) were
resuspended in Dulbecco's modified Eagle' medium (DMEM)
and allowed to infect 4×105 monocyte/macrophages at 37 °C
for 16 h. The unbound viruses were washed off, via three
vigorous washes with DMEM. The infected cells were then
cultured, in duplicate, in 2 ml of DMEM plus 10% FCS, 10%
horse serum, and 0.1 mM NEAA. After overnight incubation,
the supernatants (0.5 ml) were collected for HIV-1 p24 antigen
detection on day 0. The cells were then cultured in 2 ml of
DMEM plus 10% FCS, 10% horse serum, and 0.1 mM NEAA.
Samples (0.5 ml each) of the supernatants were collected at
specified time points. The HIV-1 p24 antigen levels were
quantitated by ELISA.
489E.G. Argyris et al. / Virology 353 (2006) 482–490Statistical analyses
Paired Student's t tests were utilized to compare the
differences between samples treated with different viral
preparations. All tests were two-tailed. A P value of 0.05 or
less was considered statistically significant.
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